Takeda Pharmaceutical (TAK) Net Cash Flow Growth (3y) (2021 - 2026)
Takeda Pharmaceutical (TAK) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -62.71% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 73.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.89% |
| Dec 31, 2025 | 24.24% |
| Sep 30, 2025 | 28.08% |
| Jun 30, 2025 | 49.46% |
| Mar 31, 2025 | -39.47% |
| Dec 31, 2024 | -66.65% |
| Sep 30, 2024 | 51.83% |
| Jun 30, 2024 | 39.89% |
| Mar 31, 2024 | -29.53% |
| Dec 31, 2023 | -22.84% |
| Sep 30, 2023 | -26.73% |
| Jun 30, 2023 | -57.89% |
| Mar 31, 2023 | -12.09% |
| Sep 30, 2022 | -26.90% |
| Jun 30, 2022 | -24.98% |
| Mar 31, 2022 | 44.56% |
| Dec 31, 2021 | 137.64% |
| Sep 30, 2021 | -37.80% |
| Jun 30, 2021 | -74.69% |
| Mar 31, 2021 | 73.91% |